World's Best Scientists 2026 revealed!
Award Badge
Immunology
Spain
2025
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Immunology

D-Index
109
Citations
47378
World Ranking
515
National Ranking
46

Medicine

D-Index
109
Citations
47459
World Ranking
5744
National Ranking
563

Research.com Recognitions

  • 2025 - Research.com Immunology in Spain Leader Award
  • 2023 - Research.com Medicine in Spain Leader Award
  • 2022 - Research.com Immunology in Spain Leader Award

Overview

Ignacio Melero is affiliated with the University of Navarra in Spain and has a significant focus on cancer immunotherapy and related biomedical research. Their primary fields of study include Medicine and Immunology and Microbiology, with subfields concentrating on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Hepatology.

The scientist's research topics cover a range of areas within cancer and immune system interactions. The main topics associated with their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Immune cells in cancer
  • Hepatocellular Carcinoma Treatment and Prognosis

Ignacio Melero has published extensively in various peer-reviewed journals and venues. Frequent publication outlets for their work include:

  • Annals of Oncology (28 publications)
  • Journal for ImmunoTherapy of Cancer (21 publications)
  • Regular and Young Investigator Award Abstracts (21 publications)
  • Journal of Clinical Oncology (19 publications)
  • Cancer Research (18 publications)

Their recent scientific papers reflect a concentration on immunotherapy approaches, particularly in liver cancer and tumor immunology. Notable recent publications include:

  • "Advances in immunotherapy for hepatocellular carcinoma" (2021, Nature Reviews Gastroenterology & Hepatology)
  • "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib" (2020, JAMA Oncology)
  • "Cancer vaccines: the next immunotherapy frontier" (2022, Nature Cancer)
  • "CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity" (2020, Immunity)
  • "Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors" (2020, Nature Medicine)

Collaboration has been an important aspect of their research, with several frequent coauthors, indicating sustained joint work in the field. These coauthors include:

  • Pedro Berraondo
  • Álvaro Teijeira
  • Miguel F. Sanmamed
  • María E. Rodriguez-Ruiz
  • Maite Álvarez

Best Publications

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • Dendritic cells in cancer immunology and immunotherapy.

    Stefanie K Wculek;Francisco J Cueto;Adriana M Mujal;Ignacio Melero

  • Advances in immunotherapy for hepatocellular carcinoma

    Bruno Sangro;Pablo Sarobe;Sandra Hervás-Stubbs;Ignacio Melero

  • Cytokines in clinical cancer immunotherapy

    Pedro Berraondo;Miguel F. Sanmamed;María C Ochoa;Iñaki Etxeberria

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

    Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Jun Wang;Miguel F. Sanmamed;Ila Datar;Tina Tianjiao Su

  • Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Scott Gettinger;Jungmin Choi;Katherine Hastings;Anna Truini

  • Evolving synergistic combinations of targeted immunotherapies to combat cancer.

    Ignacio Melero;David M. Berman;M. Angela Aznar;Alan J. Korman

  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.

    Álvaro Teijeira;Saray Garasa;María Gato;Carlos Alfaro

  • Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

    Deborah B. Doroshow;Miguel F. Sanmamed;Katherine Hastings;Katerina Politi

  • Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

    Kurt A. Schalper;Maria E. Rodriguez-Ruiz;Ricardo Diez-Valle;Alvaro López-Janeiro

  • Direct Effects of Type I Interferons on Cells of the Immune System

    Sandra Hervas-Stubbs;Jose Luis Perez-Gracia;Ana Rouzaut;Miguel Fernandez de Sanmamed

  • Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors

    Bruno Sangro;Guillermo Mazzolini;Juan Ruiz;Maite Herraiz

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Immunological landscape and immunotherapy of hepatocellular carcinoma

    Jesús Prieto;Ignacio Melero;Bruno Sangro

  • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.

    Kurt A. Schalper;Michael Carleton;Ming Zhou;Tian Chen

  • Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

    Alfonso R. Sánchez-Paulete;Francisco J. Cueto;María Martínez-López;Sara Labiano

  • Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

    Cariad Chester;Miguel F. Sanmamed;Jun Wang;Ignacio Melero

  • T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.

    Ignacio Melero;Ana Rouzaut;Greg T. Motz;George Coukos

Frequent Co-Authors

Jesús Prieto
Jesús Prieto University of Navarra
Bruno Sangro
Bruno Sangro University of Navarra
Sandra Hervas-Stubbs
Sandra Hervas-Stubbs University of Navarra
Masatoshi Kudo
Masatoshi Kudo Kindai University
Lieping Chen
Lieping Chen Yale University
Kurt A. Schalper
Kurt A. Schalper Yale University
Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
Tim Meyer
Tim Meyer University College London
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Juan José Lasarte
Juan José Lasarte University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various advanced nursing and healthcare roles, many of which can be pursued through specialized online degrees. For example, nurses interested in mental health can explore some of the most affordable pmhnp programs that combine immunological knowledge with psychiatric care. These programs offer a cost-effective route to becoming a Psychiatric-Mental Health Nurse Practitioner.

For those aiming at higher earnings, understanding the highest paid dnp specialties can guide your career planning. Specializing within these fields often requires additional credentials or bridge programs, such as transitioning from family nursing to more acute care settings.

If you are a Family Nurse Practitioner (FNP) looking to advance, consider an fnp to acute care np bridge program. This pathway allows you to expand your expertise to handle critically ill patients, integrating immunological principles necessary in acute care environments.

Alternatively, accelerated fnp program options are available online for those seeking to fast-track their career growth. These accelerated paths allow immunology-focused practitioners to gain credentials quicker, making it easier to transition into advanced practice roles.

Best Scientists Citing Ignacio Melero

Trending Scientists

Recently Published Articles